Abstract
Objective This study applied the public genetic databases high-throughput gene expression omnibus (GEO) database to compare the difference of gene screening between the repeated implantation failure (RIF) patients and women with normal endometrium. This study aims to provide additional information for the diagnosis and treatment in RIF patients through the gene set enrichment analysis and the construction of protein–protein interactions (PPIs) network.
Method The human endometrial microarray data of RIF and normal control group were obtained from the GEO database provided by the National Center for Biotechnology Information (NCBI). The analysis and the review of differential gene screening, gene ontology (GO) pathway analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and PPIs network construction were carried out.
Result 273 genes with differential expression, 87 up-regulated and 186 down-regulated genes, were obtained through differential gene analysis. 50 genes with the most significant differential expression fold change were screened for subsequent analysis. KEGG results indicated that the top three related pathways were cancer pathway, MAPK signaling pathway, and homologous recombination pathway when the relevant pathways were sequenced according to the correlation size. GO analysis showed that differentially expressed genes were involved in protein phosphorylation, complement activation, and other biological processes. PPIs analysis demonstrated that targeted genes show high correlation to the endometrial receptivity, including PAEP, CXCL14, HOXB3, CD55, and VEGFA, all were down-regulated in RIF endometrial tissues compared to the control group, and these genes also influenced and regulated each other.
Conclusion Through public databases and bioinformatics, several factors in endometrial receptivity that affect RIF directly and indirectly were found. In particular, the immune and angiogenesis factors stood out the most. The different genes which regulate the immune response and angiogenesis response may become new targeted treatment for RIF.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Youth Research Program of the first hospital of Lanzhou University (no.ldyyyn2018-05)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data were obtained from the GEO database provided by the National Center for Biotechnology Information (NCBI).
